http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103275151-B

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-08
filingDate 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103275151-B
titleOfInvention A kind of process for purification of Matachrom
abstract The invention provides a kind of process for purification of Matachrom.A process for purification for Matachrom, mainly comprises (1) and carries out preliminary decolouring impurity elimination to erythromycin diafiltration liquid flocculation agent, extract after being purified liquid with erythromycin special solvent, further to decolour impurity elimination to extraction liquid gac.(2) by process after erythromycin extraction liquid phase inversion to purifying aqueous phase, again the erythromycin in aqueous phase is extracted in N-BUTYL ACETATE, cyclohexane mixed solvent, utilize the method for two-step crystallization to obtain erythromycin crystal liquid, be dried after separation to Matachrom finished product.In finished product, Erythromycin A content reaches more than 83%.The present invention is directed to traditional processing technology utilizes special solvent to extract erythromycin from erythromycin diafiltration liquid, then the crystallization of extraction liquid is carried out, finally be dried after separation to the shortcoming that in Matachrom finished product, Erythromycin A content is low, decolouring impurity elimination is carried out to diafiltration liquid and extraction liquid, the method of two-step crystallization after phase inversion, improves the content of Erythromycin A in Matachrom finished product.
priorityDate 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002038020-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03027049-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4398339
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419561163
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420189551
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15506
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407386600
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22525221
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419561719
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56927991
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415967723
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585704
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425258636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484729
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419588230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585724
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453315515
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID83933
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447043
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5480431
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8078
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12560
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516871
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9918244

Total number of triples: 38.